The highly consistent efficacy data across two independent Phase 2 trials strengthens the probability of success for ORKA-001. Key catalysts to watch: 52-week EVERLAST-A data in December 2026, Phase 3 initiation in 1H 2027, and ORKA-002 data in Q1 2027. The $1.1B cash runway removes near-term financing risk.
Price Chart
Executive Summary
Oruka Therapeutics announced positive Week 16 results from its Phase 2b EVERLAST-B trial of ORKA-001 in moderate-to-severe plaque psoriasis. The high-dose (600 mg) group achieved 61% PASI 100 and 86% PASI 90, consistent with prior EVERLAST-A results, with a favorable safety profile. The company plans to initiate Phase 3 trials in the first half of 2027 and has a cash runway of $1.1 billion through a BLA filing.
Key Facts
- EVERLAST-B Phase 2b trial of ORKA-001 met primary endpoint: 61% PASI 100 at Week 16 in the 600 mg high-dose group vs. 0% for placebo (p<0.0001)
- High-dose group also achieved 86% PASI 90 and 86% IGA 0/1 at Week 16
- Results consistent with prior EVERLAST-A trial (63% PASI 100, 83% PASI 90 at Week 16)
- Favorable safety profile: 39% TEAEs in high-dose group vs. 43% placebo; no serious TEAEs in high-dose group; no injection site reactions across all ORKA-001 doses
- Company plans to initiate Phase 3 trials in moderate-to-severe PsO in 1H 2027 with the 600 mg high dose
- 52-week EVERLAST-A data expected December 2026; 52-week EVERLAST-B data expected 2H 2027
- Cash, cash equivalents, and marketable securities of $1.1 billion as of June 30, 2026, expected to fund operations through BLA filing
- Company also expects Week 16 results from ORKA-002 Phase 2 PsO trial in Q1 2027
Financial Impact
No revenue or earnings data; clinical-stage biotech with $1.1B cash position. Positive Phase 2b data supports advancement to Phase 3, de-risking the program.
Risk Factors
- Cross-trial comparisons to approved IL-23 inhibitors are not head-to-head; Phase 3 data may show different relative efficacy
- Long-term durability and safety data (52-week) not yet available; expected in December 2026 and 2H 2027
- Regulatory interactions for Phase 3 design are pending; could affect trial timelines
- Clinical-stage company with no approved products; regulatory and commercial risks remain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-112281 |
| Document: ea030959401ex99-2.htm | 0001213900-26-112281 |
| Document: ea030959401ex99-1.htm | 0001213900-26-112281 |
| Document: 0001213900-26-112281-index-headers.html | 0001213900-26-112281 |
| Document: 0001213900-26-112281-index.html | 0001213900-26-112281 |
| Document: 0001213900-26-112281.txt | 0001213900-26-112281 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $78.50 | awaiting T+5 | — | $96.19 (+22.54%) |
Oct 25, 2026 2d ago | Press Release | $80.15 | awaiting T+5 | — | $96.19 (+20.01%) |
Oct 20, 2026 6d ago | Insider Cluster | $79.92 | awaiting T+5 | — | $96.19 (+20.36%) |
Oct 15, 2026 11d ago | Insider Cluster | $71.93 $80.15 | ▲ +11.43% | ▲ +11.86% | $96.19 (+33.73%) |
Sep 21, 2026 5w ago | Insider Cluster | $94.55 $82.15 | ▲ +13.11% | ▲ +11.93% | $96.19 (−1.73%) |
Sep 15, 2026 5w ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $96.19 (+2.82%) |
Sep 1, 2026 7w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $96.19 (−4.98%) |
Aug 28, 2026 8w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $96.19 (−5.54%) |
Aug 17, 2026 10w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $96.19 (−14.94%) |
Aug 10, 2026 11w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $96.19 (−8.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers